Overview

Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Locally Advanced Rectal Cancer - a Multicenter, Single-arm, Open-label Clinical Trail

Status:
Not yet recruiting

Trial end date:
2024-05-31

Target enrollment:

Participant gender:

Summary

Evaluation of the efficacy and safety of interleucin-2 combined with PD-1 monoclonal antibody and CAPOX in preoperative neoadjuvant therapy for locally advanced rectal cancer - a multicenter, single-arm, open-label clinical trail.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

The First Affiliated Hospital with Nanjing Medical University

Treatments:

Interleukin-2